Second-generation ALK-TKIs, i.e., alectinib [26,27] and ceritinib [28], characterized by a different sensitivity-spectrum to ALK resistance mutations, have been approved as a treatment of NSCLC following resistance to crizotinib [25]. This evidence concerns the gene ALK and non-small cell lung carcinoma.